http://hdl.handle.net/2268/100 Search this channel search http://orbi.ulg.ac.be/simple-search http://hdl.handle.net/2268/148080 Title: Belgian multicentre experience with intestinal transplantation <br/> <br/>Author, co-author: Ceulemans, L; DE ROOVER, Arnaud; DETRY, Olivier; Troisi, R; Rogiers, X; Reding, R; Lerut, J; Ysebaert, D; Chapelle, T; Monbaliu, D; Pirenne, J http://hdl.handle.net/2268/148055 Title: Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease. <br/> <br/>Author, co-author: De Greef, E.; Hoffman, I.; D'Haens, G.; Van Biervliet, S.; Smets, F.; Scaillon, M.; Dewit, Olivier; Peeters, H.; Paquot, I.; Alliet, P.; Arts, W.; Hauser, B.; Vermeire, S.; Van Gossum, A.; Rahier, J. F.; Etienne, I.; Louis, Edouard; Coche, J. C.; Mahachie John, Jestinah; Van Steen, Kristel; Veereman, G. <br/> <br/>Abstract: Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in Belgian pediatric Crohn's disease patients. All patients on infliximab as part of the present or past treatment for Crohn's Disease until January 1st 2011 were selected from an existing database. Information on disease phenotype, medication and adverse events were extracted. Adverse events occurred in 25.9% of patients exposed to infliximab of which 29.6% were severe. In total 31.7% of patients stopped infliximab therapy. The main reasons for discontinuation were adverse events in 45.4% and loss of response in 30.3%. No malignancies or lethal complications occurred over this 241 patient year observation period. Immunomodulators were concomitant medication in 75% of patients and were discontinued subsequently in 38.4% of them. The cost of infliximab infusions per treated patient per year in the Belgian health care setting is approximately 9 474 euro, including only medication and hospital related costs. Even though infliximab is relatively safe in pediatric CD on the short term, close follow-up and an increased awareness of the possible adverse reactions is highly recommended. Adverse reactions appeared in 25.9% of all patients and were the main reason for discontinuation. Treatment cost has to be balanced against efficacy and modifications in disease course. In the Belgian health care system, the medication is available to all patients with moderate to severe CD. http://hdl.handle.net/2268/147869 Title: Is ultra-short cold ischemia the key to ischemic cholangiopathy avoidance in DCD-LT? <br/> <br/>Author, co-author: DETRY, Olivier; DE ROOVER, Arnaud; Cheham, S; Ledinh, H; COIMBRA MARQUES, Carla; DECKER, Emmanuel; KOHNEN, Laurent; HANS, Marie-France; JORIS, Jean; LAUWICK, Séverine; KABA, Abdourahmane; DELWAIDE, Jean; MEURISSE, Michel; HONORE, Pierre http://hdl.handle.net/2268/147680 Title: Retrospective analysis of Belgian experience with intestinal transplantation <br/> <br/>Author, co-author: Ceulemans, L.J.; DE ROOVER, Arnaud; DETRY, Olivier; Troisi, R; Rogiers, X; Reding, R; Lerut, J; Ysebaert, D; Chapelle, T; Monbaliu, D; Pirenne, J <br/> <br/>Abstract: Aim: The only alternative to Total Parenteral Nutrition (TPN) for complicated intestinal failure is Intesti- nal Transplantation (ITx) which is perceived as a high-risk procedure with inferior results compared to other organ Tx. Therefore ITx has been rarely applied in Belgium. In a multicenter retrospective review, we analyzed the overall Belgian experience with ITx. Methods: The Belgium Liver Intestine Committee organized a survey among all Belgian Tx centers, based on the patient-specific data form of the international ITx registry. Overall activity and indications were reviewed. Patient/graft survival was calculated (Kaplan-Meier). Nutritional (TPN) independence and Quality of Life (QoL) (Karnofsky score) were analyzed. Results: 21 ITx were performed in 20 patients (03/99-11/12), distributed among 5 centers: KUL (12), ULg (5), UZG (2), UCL (1), UZA (1). Median age was 38y(8mo-56y). Male/female ratio was 10/10. 5 were pediatrics (<18y) and 15 adults. Indications were anatomical or functional short bowel syndrome: intestinal ischemia(5), volvulus(5), Crohn(2), chronic intestinal pseudo-obstruction(2), splanchnic thrombosis(2), Churg-Strauss(1), necrotizing enterocolitis(1), microvillus inclusion(1), intestinal atresia(1) and chronic rejection of a first ITx(1). Most patients also suffered from TPN-associated com- plications (infection/shortage of venous access or liver failure). An isolated small bowel was trans- planted in 9 patients (plus kidney Tx in 2; plus pancreas Tx in 1); 10 received a combined liver and ITx; 2 received a multivisceral Tx. At time of Tx, 11 patients were hospitalized and 10 at home. 20 grafts were procured from deceased donors; one segmental intestinal graft was procured from a living donor. ABO blood group was identical in 63%, compatible in 37%. Median cold ischemia time was 5h30 ́(3h17 ́-9h31 ́). All patients received tacrolimus-based immunosuppression. Basiliximab (anti-IL2 receptor antibody) induction was administered in 16 patients. In 11 patients donor specific blood was transfused as part of an immunomodulatory protocol. 5-year patient and graft survival is 59% and 55.6%, respectively. 8 patients died: 6 to sepsis, 1 to intracerebral hemorrhage; 1 sudden death re- mained unexplained. 1 patient developed postTx lymphoma. 2 chronic rejections occured for which one reTx was performed. Of 12 survivors (median follow-up 1870 days), 11 are nutritionally independent (TPN-free) and 10 have a Karnofsky score >90%. Conclusions: ITx has come of age in Belgium. During the last 13 years, 21 ITx were performed in 5 centers. A 5-year patient/graft survival of 59%/55.6% is achieved, which is similar to results reported by the International ITx registry. In Belgium, awareness should grow that ITx represents a life-saving (and QoL improving) treatment in selected patients with reduced life expectancy due to significant complica- tions from TPN and intestinal failure. http://hdl.handle.net/2268/147543 Title: Diagnostic des allergies via bilan IgE spécifiques. Les méfaits des bilans d'IgG alimentaires <br/> <br/>Author, co-author: GADISSEUR, Romy http://hdl.handle.net/2268/144493 Title: Is ultra-short cold ischemia the key to IBDL avoidance in DCD-LT? <br/> <br/>Author, co-author: DETRY, Olivier; DE ROOVER, Arnaud; Ledinh, Hieu; HANS, Marie-France; LAUWICK, Séverine; MEURISSE, Michel; DELWAIDE, Jean; HONORE, Pierre http://hdl.handle.net/2268/144458 Title: Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single center cohort study <br/> <br/>Author, co-author: Breynaert, C; Ferrante, M; Fidder, H; Van Steen, Kristel; Noman, M; Ballet, V; Vermeire, S; Rutgeerts, P; Van Assche, G http://hdl.handle.net/2268/144455 Title: Active Foxp3 (+) Regulatory T Cells Rather Than Other Foxp3 (+) T Cells Subsets CorrelateWith Clinical Response To Infliximab Therapy For IBD <br/> <br/>Author, co-author: Li, Z; Vermeire, S; Bullens, D; Ferrante, M; Van Steen, Kristel; Noman, M; Rutgeerts, P; Ceuppens, J L; Van Assche, G http://hdl.handle.net/2268/144454 Title: Restoration Of B Cells Correlates With Clinical Response To Anti-Tnf Therapy <br/> <br/>Author, co-author: Li, Z; Vermeire, S; Bullens, D; Ferrante, M; Van Steen, Kristel; Noman, M; Rutgeerts, P; Ceuppens, J L; Van Assche, G http://hdl.handle.net/2268/144453 Title: Therapeutic Strategy and Patient Outcome during the First 2 Years of Pediatric Crohn’s Disease <br/> <br/>Author, co-author: Veereman, G; Mahachie John, Jestinah; De Greef, E; Smets, F; Van Biervliet, S; Van Steen, Kristel http://hdl.handle.net/2268/144452 Title: Therapeutic Strategy and Patient Outcome during the First 2 Years of Pediatric Crohn’s Disease <br/> <br/>Author, co-author: Veereman, G; Mahachie John, Jestinah; De Greef, E; Smets, F; Van Biervliet, S; Van Steen, Kristel http://hdl.handle.net/2268/144451 Title: Safety And Cost Of Infliximab For The Treatment Of Belgian Pediatric Patients With Crohn’s Disease <br/> <br/>Author, co-author: De Greef, E; Hoffman, I; D'haens, G; Van Biervliet, S; Smets, F; Scaillon, M; Dewit, O; Peeters, H; Paquot, I; Alliet, P; Arts, W; Hauser, B; Vermeire, S; Van Gossum, A; Rahier, J F; Etienne, I; Louis, E; Coche, J C; Mahachie John, Jestinah; Van Steen, Kristel; Veereman, G http://hdl.handle.net/2268/144438 Title: Safety And Cost Of Infliximab For The Treatment Of Belgian Pediatric Patients With Crohn’s Disease <br/> <br/>Author, co-author: De Greef, E; Hoffman, I; D'haens, G; Van Biervliet, S; Smets, F; Scaillon, M; De Wit, O; Peeters, H; Paquot, I; Alliet, P; Arts, W; Hauser, B; Vermeire, S; Van Gossum, A; Rahier, J F; Etienne, I; Louis, E; Coche, J C; Mahachie John, Jestinah; Van Steen, Kristel; Veereman, G http://hdl.handle.net/2268/144371 Title: Factors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn’s disease patients (BELCRO) <br/> <br/>Author, co-author: De Greef, E; Mahachie John, Jestinah; Hoffman, I; Smets, F; Van Biervliet, S; Scaillon, M; Hauser, B; Paquot, I; Alliet, P; Arts, W; Dewit, O; Baert, F; D'haens, G; Rahier, J F; Etienne, I; Bauraind, O; Van Gossum, A; Vermeire, S; Fontaine, F; Muls, V; Louis, E; Van de Mierop, F; Coche, J C; Van Steen, Kristel; Veereman, G http://hdl.handle.net/2268/144369 Title: Factors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn's disease patients (BELCRO) <br/> <br/>Author, co-author: De Greef, E; Mahachie John, Jestinah; Hoffman, I; Smets, F; Van Biervliet, S; Hauser, B; Paquot, I; Alliet, P; Arts, W; Dewit, O; Peeters, H; Baert, F; D'haens, G; Rahier, J F; Etienne, I; Bauraind, O; Van Gossum, A; Vermeire, S; Fontaine, F; Muls, V; Louis, E; Van de Mierop, F; Coche, J C; Van Steen, Kristel; Veereman, G http://hdl.handle.net/2268/144368 Title: Genetic and functional evidence for a role of CYLD in Crohn’s Disease: results from a European consortium <br/> <br/>Author, co-author: Cleynen, I; Vazeille, E; Artieda, M; Szczypiorska, M; Bringer, M-A; Verspaget, W; Lakatos, P; Seibold, F; Parnell, K; Weersma, R; Mahachie John, Jestinah; Morgan-Walsh, R; Staelens, D; Arijs, I; Müller, S; Tordai, A; Hommes, D; Ahmad, T; Wijmenga, C; Pender, S; Rutgeerts, P; Lottaz, D; Van Steen, Kristel; Vermeire, S; Darfeuille-Michaud, A http://hdl.handle.net/2268/144367 Title: Multiple functional variants at the 3p21 locus contribute to ulcerative colitis: Results from a European consortium <br/> <br/>Author, co-author: Cleynen, I; Artieda, M; Verspaget, H; Lakatos, P; Seibold, F; Ahmad, T; Weersma, R; Arijs, I; Mahachie John, J; Müller, S; Tordai, A; Hommes, D; Parnell, K; Van Steen, Kristel; Wijmenga, C; Rutgeerts, P; Lottaz, D; Vermeire, S http://hdl.handle.net/2268/144366 Title: Sequential T2 Relaxometry as a Non-Invasive Assessment of Transmural Inflammation in a Murine Model of Chronically Relapsing Colitis <br/> <br/>Author, co-author: Breynaert, C; Dresselaers, T; Cremer, J; Van Steen, Kristel; Perrier, C; Vermeire, S; Rutgeerts, P; Ceuppens, J; Himmelreich, U; Van Assche, G http://hdl.handle.net/2268/144364 Title: Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. <br/> <br/>Author, co-author: Joossens, Marie; Van Steen, Kristel; Branche, Julien; Sendid, Boualem; Rutgeerts, Paul; Vasseur, Francis; Poulain, Daniel; Broly, Franck; Colombel, Jean*-Frederic; Vermeire, Severine; Chamaillard, Mathias <br/> <br/>Abstract: BACKGROUND:: An increased risk of Crohn's disease (CD) has been reported consistently in first-degree relatives of patients. Our aim was to test whether a combination of CD-associated genes involved in innate immunity and/or antibody responses to microbial antigens may be valuable in identifying healthy relatives at risk. METHODS:: We investigated 86 families from Belgium and northern France, 45 with at least 3 first-degree relatives with CD, 24 with a single case, and 17 control families without inflammatory bowel disease (IBD). The cohort consisted of 186 CD patients, 290 healthy relatives, and 142 controls (total 618). Genetic (NOD2, NOD1, TLR4, CARD8) and serologic markers (ASCA, ACMA, ALCA, ACCA, ASigmaMA, OmpC, CBir1, I2) were determined in all subjects. All Belgian families were prospectively followed up for 54 months. RESULTS:: In multiple-affected families, an increment of affected first-degree relatives and of positive antibodies were additive risks factors for CD (P < 0.0001), independent of NOD2 mutations. When comparing subjects from multiple-affected families, having 3 additional first-degree relatives with CD and 1 additional positive antibody increased the odds for CD to 9.19 (95% confidence interval [CI]: 4.07-20.80). After a follow-up of 54 months among all Belgian families, a total of 4 new diagnoses of IBD were confirmed in the multiple-affected families only, resulting in a 57-fold increase in incidence within multiple-affected families compared to the known incidence of IBD in our region. CONCLUSIONS:: We found an additive risk increment for CD in subjects from multicase families per additional affected relative and per additional positive antibody, independent of NOD2. Furthermore, a very high disease incidence was observed in these multiple-affected families. Inflamm Bowel Dis 2010. http://hdl.handle.net/2268/144363 Title: Repeated cycles of DSS inducing a chronically relapsing inflammation: a novel model to study fibrosis using in vivo MRI T2 relaxometry <br/> <br/>Author, co-author: Breynaert, C; Dresselaers, T; Cremer, J; Van Steen, Kristel; Perrier, C; Vermeire, S; Rutgeerts, P; Ceuppens, J; Himmelreich, U; Van Assche, G